Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis
Autologous hematopoietic cell transplant (aHCT) has a significant survival advantage in patients with high‐risk (HR) neuroblastoma. Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a serious complication and may result in chronic renal disease leading to delay in subsequent posttransplan...
Gespeichert in:
| Veröffentlicht in: | Pediatric blood & cancer 2021-03, Vol.68 (3), p.e28852-n/a |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e28852 |
| container_title | Pediatric blood & cancer |
| container_volume | 68 |
| creator | Emberesh, Myesa Rubinstein, Jeremy D. Young, Jennifer Benoit, Stefanie W. Dandoy, Christopher E. Weiss, Brian D. |
| description | Autologous hematopoietic cell transplant (aHCT) has a significant survival advantage in patients with high‐risk (HR) neuroblastoma. Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a serious complication and may result in chronic renal disease leading to delay in subsequent posttransplant therapy and limitations of treatment options. Dinutuximab represents an important therapeutic advance in the treatment of pediatric HR neuroblastoma, but historically has not been administered in patients with GFR |
| doi_str_mv | 10.1002/pbc.28852 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2474465895</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2474465895</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-8a7205de7de426801e11ab64b99719a2881435e382d3321113654a8c3ffca38b3</originalsourceid><addsrcrecordid>eNp10ctO3DAUBmCrAhVKu-gLIEts2sUMvsSJsywjbhISXdB1dJKcMKaJHWxHw-y6Ys0z9knqYYBFJVa2rE__sc5PyFfO5pwxcTzWzVxorcQHss9VpmaK8WLn7c7KPfIphLtEc6b0R7InpdS85MU-ebxxPXqwDVLX0dbYKU4PZoCaxmV6H9e0c55GjxAHtHGDluZ2-ffPkzfhN7U4eVf3EKIbgBpL48rREaJJNtCViUuKtk06RLhF6tFCn6YEhJAG2nSFfh1M-Ex2O-gDfnk5D8ivs9ObxcXs6vr8cvHjatZIJcVMQyGYarFoMRO5Zhw5hzrP6rIseAlpBzyTCqUWrZSCcy5zlYFuZNc1IHUtD8i3be7o3f2EIVaDCQ32PVh0U6hEVmRZrnSpEj36j965yaf_b1Saw0tWsqS-b1XjXQgeu2r0aX1-XXFWbcqpUjnVcznJHr4kTvWA7Zt8bSOB4y1YmR7X7ydVP08W28h_TdabdA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2481419090</pqid></control><display><type>article</type><title>Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis</title><source>Access via Wiley Online Library</source><creator>Emberesh, Myesa ; Rubinstein, Jeremy D. ; Young, Jennifer ; Benoit, Stefanie W. ; Dandoy, Christopher E. ; Weiss, Brian D.</creator><creatorcontrib>Emberesh, Myesa ; Rubinstein, Jeremy D. ; Young, Jennifer ; Benoit, Stefanie W. ; Dandoy, Christopher E. ; Weiss, Brian D.</creatorcontrib><description>Autologous hematopoietic cell transplant (aHCT) has a significant survival advantage in patients with high‐risk (HR) neuroblastoma. Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a serious complication and may result in chronic renal disease leading to delay in subsequent posttransplant therapy and limitations of treatment options. Dinutuximab represents an important therapeutic advance in the treatment of pediatric HR neuroblastoma, but historically has not been administered in patients with GFR < 60 mL/m2/min. Here, we present the safe outcome of dinutuximab administration while on renal replacement therapy in two cases of HR neuroblastoma with end‐stage renal disease secondary to TA‐TMA.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.28852</identifier><identifier>PMID: 33381917</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Autografts ; Dialysis ; dinutuximab ; end‐stage renal disease ; Hematology ; Immunological tolerance ; Immunotherapy ; Kidney diseases ; Kidney transplantation ; Monoclonal antibodies ; Neuroblastoma ; Oncology ; Patients ; Pediatrics ; Targeted cancer therapy ; Thrombotic microangiopathy ; transplant‐associated thrombotic microangiopathy</subject><ispartof>Pediatric blood & cancer, 2021-03, Vol.68 (3), p.e28852-n/a</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020 Wiley Periodicals LLC.</rights><rights>2021 Wiley Periodicals LLC</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-8a7205de7de426801e11ab64b99719a2881435e382d3321113654a8c3ffca38b3</citedby><cites>FETCH-LOGICAL-c3532-8a7205de7de426801e11ab64b99719a2881435e382d3321113654a8c3ffca38b3</cites><orcidid>0000-0002-1934-2954 ; 0000-0002-7597-1413 ; 0000-0002-4001-9203 ; 0000-0003-3402-402X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.28852$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.28852$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33381917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Emberesh, Myesa</creatorcontrib><creatorcontrib>Rubinstein, Jeremy D.</creatorcontrib><creatorcontrib>Young, Jennifer</creatorcontrib><creatorcontrib>Benoit, Stefanie W.</creatorcontrib><creatorcontrib>Dandoy, Christopher E.</creatorcontrib><creatorcontrib>Weiss, Brian D.</creatorcontrib><title>Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis</title><title>Pediatric blood & cancer</title><addtitle>Pediatr Blood Cancer</addtitle><description>Autologous hematopoietic cell transplant (aHCT) has a significant survival advantage in patients with high‐risk (HR) neuroblastoma. Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a serious complication and may result in chronic renal disease leading to delay in subsequent posttransplant therapy and limitations of treatment options. Dinutuximab represents an important therapeutic advance in the treatment of pediatric HR neuroblastoma, but historically has not been administered in patients with GFR < 60 mL/m2/min. Here, we present the safe outcome of dinutuximab administration while on renal replacement therapy in two cases of HR neuroblastoma with end‐stage renal disease secondary to TA‐TMA.</description><subject>Autografts</subject><subject>Dialysis</subject><subject>dinutuximab</subject><subject>end‐stage renal disease</subject><subject>Hematology</subject><subject>Immunological tolerance</subject><subject>Immunotherapy</subject><subject>Kidney diseases</subject><subject>Kidney transplantation</subject><subject>Monoclonal antibodies</subject><subject>Neuroblastoma</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Targeted cancer therapy</subject><subject>Thrombotic microangiopathy</subject><subject>transplant‐associated thrombotic microangiopathy</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10ctO3DAUBmCrAhVKu-gLIEts2sUMvsSJsywjbhISXdB1dJKcMKaJHWxHw-y6Ys0z9knqYYBFJVa2rE__sc5PyFfO5pwxcTzWzVxorcQHss9VpmaK8WLn7c7KPfIphLtEc6b0R7InpdS85MU-ebxxPXqwDVLX0dbYKU4PZoCaxmV6H9e0c55GjxAHtHGDluZ2-ffPkzfhN7U4eVf3EKIbgBpL48rREaJJNtCViUuKtk06RLhF6tFCn6YEhJAG2nSFfh1M-Ex2O-gDfnk5D8ivs9ObxcXs6vr8cvHjatZIJcVMQyGYarFoMRO5Zhw5hzrP6rIseAlpBzyTCqUWrZSCcy5zlYFuZNc1IHUtD8i3be7o3f2EIVaDCQ32PVh0U6hEVmRZrnSpEj36j965yaf_b1Saw0tWsqS-b1XjXQgeu2r0aX1-XXFWbcqpUjnVcznJHr4kTvWA7Zt8bSOB4y1YmR7X7ydVP08W28h_TdabdA</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Emberesh, Myesa</creator><creator>Rubinstein, Jeremy D.</creator><creator>Young, Jennifer</creator><creator>Benoit, Stefanie W.</creator><creator>Dandoy, Christopher E.</creator><creator>Weiss, Brian D.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1934-2954</orcidid><orcidid>https://orcid.org/0000-0002-7597-1413</orcidid><orcidid>https://orcid.org/0000-0002-4001-9203</orcidid><orcidid>https://orcid.org/0000-0003-3402-402X</orcidid></search><sort><creationdate>202103</creationdate><title>Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis</title><author>Emberesh, Myesa ; Rubinstein, Jeremy D. ; Young, Jennifer ; Benoit, Stefanie W. ; Dandoy, Christopher E. ; Weiss, Brian D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-8a7205de7de426801e11ab64b99719a2881435e382d3321113654a8c3ffca38b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Autografts</topic><topic>Dialysis</topic><topic>dinutuximab</topic><topic>end‐stage renal disease</topic><topic>Hematology</topic><topic>Immunological tolerance</topic><topic>Immunotherapy</topic><topic>Kidney diseases</topic><topic>Kidney transplantation</topic><topic>Monoclonal antibodies</topic><topic>Neuroblastoma</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Targeted cancer therapy</topic><topic>Thrombotic microangiopathy</topic><topic>transplant‐associated thrombotic microangiopathy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Emberesh, Myesa</creatorcontrib><creatorcontrib>Rubinstein, Jeremy D.</creatorcontrib><creatorcontrib>Young, Jennifer</creatorcontrib><creatorcontrib>Benoit, Stefanie W.</creatorcontrib><creatorcontrib>Dandoy, Christopher E.</creatorcontrib><creatorcontrib>Weiss, Brian D.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Emberesh, Myesa</au><au>Rubinstein, Jeremy D.</au><au>Young, Jennifer</au><au>Benoit, Stefanie W.</au><au>Dandoy, Christopher E.</au><au>Weiss, Brian D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr Blood Cancer</addtitle><date>2021-03</date><risdate>2021</risdate><volume>68</volume><issue>3</issue><spage>e28852</spage><epage>n/a</epage><pages>e28852-n/a</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>Autologous hematopoietic cell transplant (aHCT) has a significant survival advantage in patients with high‐risk (HR) neuroblastoma. Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a serious complication and may result in chronic renal disease leading to delay in subsequent posttransplant therapy and limitations of treatment options. Dinutuximab represents an important therapeutic advance in the treatment of pediatric HR neuroblastoma, but historically has not been administered in patients with GFR < 60 mL/m2/min. Here, we present the safe outcome of dinutuximab administration while on renal replacement therapy in two cases of HR neuroblastoma with end‐stage renal disease secondary to TA‐TMA.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33381917</pmid><doi>10.1002/pbc.28852</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-1934-2954</orcidid><orcidid>https://orcid.org/0000-0002-7597-1413</orcidid><orcidid>https://orcid.org/0000-0002-4001-9203</orcidid><orcidid>https://orcid.org/0000-0003-3402-402X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2021-03, Vol.68 (3), p.e28852-n/a |
| issn | 1545-5009 1545-5017 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2474465895 |
| source | Access via Wiley Online Library |
| subjects | Autografts Dialysis dinutuximab end‐stage renal disease Hematology Immunological tolerance Immunotherapy Kidney diseases Kidney transplantation Monoclonal antibodies Neuroblastoma Oncology Patients Pediatrics Targeted cancer therapy Thrombotic microangiopathy transplant‐associated thrombotic microangiopathy |
| title | Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A52%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tolerance%20of%20dinutuximab%20therapy%20for%20treatment%20of%20high%E2%80%90risk%20neuroblastoma%20in%20two%20patients%20with%20end%E2%80%90stage%20renal%20disease%20on%20dialysis&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Emberesh,%20Myesa&rft.date=2021-03&rft.volume=68&rft.issue=3&rft.spage=e28852&rft.epage=n/a&rft.pages=e28852-n/a&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.28852&rft_dat=%3Cproquest_cross%3E2474465895%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2481419090&rft_id=info:pmid/33381917&rfr_iscdi=true |